Patients with ANO1 mutations who received combined therapy demonstrated longer progression-free survival, indicating that ANO1 may serve as an effective biomarker for predicting the efficacy of dual blockade therapy in NSCLC with PD-(L)1/CTLA-4 (151). Here, ANO1 is linked to non-small cell lung carcinoma.